FDA Approves Oral TYK2 Inhibitor for Treating Psoriasis FDA Approves Oral TYK2 Inhibitor for Treating Psoriasis

Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, is the first drug in this class to be approved.FDA Approvals

Source: Medscape Dermatology Headlines - September 12, 2022 Category: Dermatology Tags: Dermatology News Alert Source Type: news